Evidence map›Paper›PMID 32814862›Full record

ReviewNature reviews. Microbiology2021

Nanomaterial-based therapeutics for antibiotic-resistant bacterial infections.

Jessa Marie V Makabenta, Ahmed Nabawy, Cheng-Hsuan Li, Suzannah Schmidt-Malan, Robin Patel, Vincent M Rotello

Open access · greenAbstract readReview
In one paragraph

Review in Nature reviews. Microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 454 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
454citing papers in PubMed, 2 pooled it
48.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

454 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,292 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. NIR-Assisted Multimodal Strategies for Enhanced Antibacterial Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. HAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  17. Article
  18. Review
  19. Article
  20. Review

394 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jessa Marie V MakabentaDepartment of Chemistry, University of Massachusetts Amherst, Amherst, MA, USA.ORCID http://orcid.org/0000-0002-2062-7914
Ahmed NabawyDepartment of Chemistry, University of Massachusetts Amherst, Amherst, MA, USA.ORCID http://orcid.org/0000-0001-6505-4606
Cheng-Hsuan LiDepartment of Chemistry, University of Massachusetts Amherst, Amherst, MA, USA.ORCID http://orcid.org/0000-0002-3334-5756
Suzannah Schmidt-MalanDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Robin PatelDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Vincent M RotelloDepartment of Chemistry, University of Massachusetts Amherst, Amherst, MA, USA. rotello@chem.umass.edu.ORCID http://orcid.org/0000-0002-5184-5439
University of Massachusetts Amherst · USMayo Clinic in Arizona · US

Funding

Engineered Polymer Nanoemulsions for Treatment of Wound Biofilm InfectionsR01AI134770 · NIAID · UNIVERSITY OF MASSACHUSETTS AMHERST · PI Robin Patel, VINCENT M. ROTELLO · 2018 to 2026
$3.5M
NIAID NIH HHS R01 AI134770
6 · The paper itself

Abstract

Antibiotic-resistant bacterial infections arising from acquired resistance and/or through biofilm formation necessitate the development of innovative 'outside of the box' therapeutics. Nanomaterial-based therapies are promising tools to combat bacterial infections that are difficult to treat, featuring the capacity to evade existing mechanisms associated with acquired drug resistance. In addition, the unique size and physical properties of nanomaterials give them the capability to target biofilms, overcoming recalcitrant infections. In this Review, we highlight the general mechanisms by which nanomaterials can be used to target bacterial infections associated with acquired antibiotic resistance and biofilms. We emphasize design elements and properties of nanomaterials that can be engineered to enhance potency. Lastly, we present recent progress and remaining challenges for widespread clinical implementation of nanomaterials as antimicrobial therapeutics.

Indexed as

Anti-Bacterial AgentsBacteriaBacterial InfectionsBiofilmsCoinfectionDrug CarriersDrug DiscoveryDrug Resistance, BacterialHumansNanostructuresTranslational Research, BiomedicalAnti-Bacterial AgentsDrug Carriers

Identifiers

PMID32814862
PMCPMC8559572
OpenAlexW3072334995

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.